Immunohistochemical Expression of IGF-1R In cutaneous and Mucocutaneous Sqamous Cell Carcinoma

  • Muhammad Abdelrahman Abdelfattah Muhammad Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
  • Doaa Abdallah Shaban Department of Pathology, Faculty of Medicine, Port said University, port said, Egypt
  • Azza H. M. Zidan Lecturer of pathology, faculty of medicine, Suez Canal university, Ismailia, Egypt
  • Mohamed O El-Okda Lecturer of pathology, faculty of medicine, Suez Canal university, Ismailia, Egypt
Keywords: squamous cell carcinoma, insulin-like growth factor-1 receptor, immunohistochemistry, cancer, tyrosine kinase.

Abstract

Background: IGF-1R is a transmembrane receptor belongs to class of tyrosine kinase receptors, found in many tumors and is often associated with an aggressive phenotype. IGF-1R is important for regulation of growth, differentiation and apoptosis, as such, could be a pre¬ferred target for therapeutic interventions. Aim:Investigate the expression pattern of IGF-1R in different histological grades of cutaneous and mucocutaneous squamous cell carcinoma and correlate with clinicopathological prognostic factors. Materials: Forty-eight specimens of cSCC were stained immunohistochemically with IGF-1R monoclonal antibody and correlated with different clinicopathologic factors. Results: All tumors showed a degree of positivity of IGF-1R cytoplasmic and membranous expression, however; with variable degrees. High grade tumors had significantly higher IGF-1R expression than low grade tumors. IGF-1R expression showed a strong positive correlation with the tumor grade (P<0.001). Also, IGF-1R expression showed a significant relation with the depth of invasion of SCC (P<0.001). Conclusion: IGF-1R expression is significantly associated with high grade in cutaneous and mucocutaneous squamous cell carcinoma and also associated with tumors showing deeper invasion; therefore, IGF-1R may have a role pathogenesis and progression of cutaneous and mucocutaneous squamous cell carcinoma.

References

(1) Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010; 146 (3): 283-7.

(2) Mokhtar N, Salama A, Badawy O, Khorshed E, Mohamed G, Ibrahim M, et al. Cancer Pathology Registry 2000-2011. 3rd ed. National Cancer Institute, Cairo University; 2016.

(3) Andrzej S, William BM, Jacobo W, Sylvia LA, Andrew C. Human skin expresses growth hormone but not the prolactin gene. 2000; 136(6): 476-481.

(4) Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res. 2005; 11 (4): 1563-71.

(5) Arcaro A. Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol. 2013; 4:30.

(6) Werner H & Bruchim I. The insulin–like growth factor-1 Receptor as an oncogene. Arch Physiol Biochem. 2009; 115(2): 58-71.

(7) Emina E, Nurija B, Jahn M. ETS1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis. 2004; 17: 1400-1406.

(8) Lobie PE, Breipohi W, Linocoin DT, Garcia-Arogon J, Waters MJ. Localization of the growth hormone receptor/binding protein in skin. J Endocrinol. 1990; 126: 467-471.

(9) Adda G & Pinchas C. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000 Apr 183(1):1-9.

(10) Apoluongo E. Insulin-like growth factor system and sporadic malignant melanoma. Am J Pathol. 2011; 178:26-31.

(11) Kanter-Lewensohn L, Dricu A, Girnita L, Wejde J, Larsson O. Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1between different cyclins. Growth Factors.2000;17:193-202.

(12) Keehn CA, Saeed S, Bickle K, Khalil FK, Morgan MB. Expression of insulin-like growth factor-I receptor in primary cutaneous carcinomas. J Cutan Pathol. 2004;31:368-372.

(13) Clayburgh DR, Gross ND, Proby C, Koide J, Wong MH. Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality. Head Neck. 2013; 35(1):86–93.

(14) Alcides C, Enrico M, Sheila F, Nilda GR, Rajni S, Antonio C et al. Strong Association of Insulin-Like Growth Factor1 Receptor (IGF1R) Expression and Histologic Grade in Penile Squamous Cell Carcinomas. The Journal of Urology. 2013;189(4) Suppl e390.

(15) Mark B, Stephania B, Alcides C, Sheila F, Nilda GR, Enrico M et al. Immunohistochemical Expression of the Insulin-Like Growth Factor-1 Receptor in Squamous Cell Carcinomas of the Penis. The Journal of Urology. 2014;191(4) Suppl e120.

(16) Oh ST, Eun YS, Yoo DS, Park HJ, Kim TY, Cho BK, et al. Expression of ILGF1R in conventional cutaneous squamous cell carcinoma with different histological grades of differentiation, Am J Dermatopathol. 2014; 36 (10):807-11.

(17) Gündüz Ö, Gököz Ö, Erkın G, Akan T. Comparison of Growth Hormone Receptor, IGF-1R and IGFBP-3 Between Tumoral and Non-Tumoral Areas in Non-Melanoma Skin Cancers. 2013; 29 (3): 185-92.

(18) Daniel R, Neil D, Charlotte P, Jade K, Melissa H. The Effects of Epidermal Growth Factor Receptor and Insulin-like Growth Factor 1 Receptor Inhibition on Proliferation and Intracellular Signaling In cSCCHN: Potential for Dual Inhibition as a Therapeutic Modality. Head Neck. 2013; 35 (1): 86-93.

(19) Boby k & Devipriyaa B. Insulin-like growth factor-1 receptor expression in oral squamous cell carcinoma. J Clin Exp Invest. 2011; 2 (4): 354-361.

(20) Imsumran A, Adachi Y, Yamamoto H, Li R, Wang Y, Min Y, et al. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis. 2007; 28(5): 947-56.
Published
2018-02-28
Issue
Vol 5 No 2 (2018)
Section
Original Article

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).